Dr. Mattison chairs NAM report

Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics.  Over the past half-century – with the increasing focus on evidence based treatment the use of compounded medications substantially decreased.  However, in some therapeutic areas, such as menopause, use of compounded medications continues. 

Risk Sciences International 1

The continuation of use of compounded medications represents a challenge to the USFDA because the standard evaluations of benefit and risk are not required. 

To gain guidance in this concern the FDA asked the National Academies of Sciences, Engineering and Medicine to form a consensus committee to characterize the clinical utility of compounded bioidentical hormone therapy. 

The committee was chaired by  Dr. Donald Mattison the Chief Medical Officer of Risk Sciences International and composed of a dozen clinicians and scientists who worked together over the course of 1.5 years to pull the literature on risk-benefit, and clinical utility of compounded bioidentical hormone therapy.  The publication can be downloaded here.

The committee concluded (Conclusion 9.1) that there is insufficient evidence to support the overall clinical utility of compounded bioidentical hormone therapy as treatment for menopause and male hypogonadism symptoms. 

Posted in

More RSI News

USC appoints Dr. Mattison distinguished professor

March 16, 2021
USC Arnold School of Public Health

Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…

Read News Item

RSI receives National Defence funding

March 5, 2021
Canadian Armed Forces emblem

RSI is pleased to be the recipient of funding through the DND IDEaS COVID-19 Challenge. Under the supervision of Emma Hartnett, RSI will be developing…

Read News Item

Willhite receives prestigious SOT award

December 18, 2020
Calvin Willhite RSI associate expert

Calvin C. Willhite, an Associate Expert with Risk Sciences International working on a range of toxicological risk issues, was just announced as the recipient of the prestigious…

Read News Item

RSI gives keynote

October 31, 2020
RSI logo in white

RSI experts Jennifer Go and Daniel Krewski, were recently invited to present a paper on maternal and child environmental heath during a global, virtual workshop originating in Foshan, Guangdong, China.

Read News Item